Market News AIOpen the app

MetaVia Inc. said the last patient finished the final visit for its DA-1726 clinical trial.

TrialRead the original at SEC EDGAR
Good for MTVA

MetaVia completed the last visit in its extended Phase 1 study, and earlier interim results showed a 68.1% liver-fat reduction versus placebo, plus weight and blood-sugar improvements. Full results and a planned next study are still ahead, but results so far support its drug program.

MTVA · MetaVia Inc.

AI read · Good for MTVA

The AI's read

Those findings suggest the drug may help with liver fat, weight, and blood sugar. Preliminary safety observations also supported extending treatment. Still, the completed visit is not a full report of results. The full data are due in 2027, and the next study is only planned, so the promise remains unconfirmed.

Get alerts for MTVA

Follow MetaVia Inc. (MTVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MTVA
Free on the App Store and Google Play, or on the web.